The granting of restricted stock units is a positive signal of Ginkgo Bioworks' investment in its acquisitions of Patch Biosciences and Reverie Labs. This move likely aims to retain key talent and align their interests with the company's success, potentially leading to positive developments and integration outcomes. Such actions can be viewed favorably by investors as they indicate a strategic approach to mergers and acquisitions, possibly leading to an optimistic outlook on the company's stock in the short term.